Treatment with pioglitazone, originally a type II diabetes medication that targets CISD1, inhibits IP3R-CISD1 binding and rescues the PD-related phenotypes of PINK1 and Parkin null Drosophila mutants. Here, CISD1 is linked to Parkinson disease.